CD8A and metabolic dysfunction-associated steatotic liver disease: Concordantly, preclinical studies demonstrate that ICB therapy in mice exacerbated NAFLD-HCC progression by aberrant re-activation of tissue-resident, auto-aggressive CD8+TNF+PD-1+ T cells that induce liver damage, cirrhosis, and finally tumorigenesis.4